ReLink®- a breakaway connector for IV lines

The problem with Intravenous (IV) therapy

Intravenous (IV) therapy is the most common invasive procedure in modern healthcare, with fluids delivered directly into the vein through tubing connected to a catheter device. Of the 3.8 billion IV tubes used each year(1), research shows that ~10% of tubes are forcefully ripped from the vein during the infusion(2). This IV dislodgement can result in injury to the patient, loss of fluid resources, exposure of hazardous drugs and increased risk of infection. It also creates additional work for clinicians, with up to 18-44 mins of additional time required to clean and reinstate the infusion(3).

Infusion stability with ReLink®

ReLink® is a patented breakaway connector, designed and engineered to increase safety and reduce harm caused by accidental dislodgement incidents.

Its unique design features double-sided, self-sealable ports, with weak link activation to protect the catheter placement site and loss of fluid resources. The pull force required to separate the tube from the catheter has been optimised through rigorous testing to ensure the catheter dwelling site remains protected.

After separation, both ReLink® connector parts can be simply swabbed and reconnected for rapid reinstatement of therapy, providing unrivalled efficiency for nursing staff in every environment.

ReLink® is specially engineered to enhance infusion stability by keeping connections of IV catheters to IV lines, with a controlled break away and predictable results. 

Hover over ReLink®

ReLink®  product family

ReLink® is a platform technology which is adaptable across a broad range of sectors...


ReLink Care

First generation breakaway connector for increased safety for patient and healthcare professionals. CE approved for gravitational IV. Target users in emergency and elderly care.

Hover over the image


ReLink Advanced

Next generation connector for IV therapy with pumps. Designed to meet the needs of all patient groups and be compatible with all IV fluids including blood and blood products.

Hover over the image


ReLink Veterinary

Annual market value of €35 billion in Europe and USA. Low regulatory barrier for market entry. No product modifications required for treatment of small animals.

Hover over the image


ReLink Digital

Moving IV therapy from the hospital to the home could save up to 90% of treatment costs. Continuity of care is enabled by including electronics for monitoring and communication.

Hover over the image

ReLink Logos_chemo-13-01.png

Closed System

A closed system connector device eliminates leakage of toxic liquids and vapours to safekeep healthcare professionals working with hazardous drugs such as chemotherapy.

Hover over the image

ReLink® is an advanced breakaway connector for IV lines, designed to reduce complications and costs associated with accidental disconnection events in healthcare settings, a leading challenge in hospital and homecare infusions.

Our first product ReLink® Care is now CE approved and available for sale.


The patented ReLink®  platform technology will enable healthcare providers to deliver critical fluids safely and efficiently.

ReLink® by Tada Medical AB


Meet the team

Katarina Hedbeck

Chief Executive Officer 

& Co-founder

Dr. Rebecca Bejhed

Chief Operating Officer

& Co-founder

Christopher Blacker, MD

Medical Lead

& Co-founder

Chief Technical Officer

Maria Asif

Chief Financial Officer

Puneet Gaharana

Chief Strategy Officer

Dr. Ujala Bhardwaj

Chief Quality Officer

Scientific Writer

Dr. Rakshita Singh 

Chief Communication Officer

Pallavi Saksena

Design Manager

Dr. Mohit Narwal

Dr. Puneet Rinwa

Scientific Writer

Finance Controller

Elena Davydova

HR Manager

Sike Wan, MD

HEOR & RWE Manager

Hasanain Alattar

Project Manager


Tada Medical News

A snapshot of what's keeping us inspired, excited and busy! 

Follow us on:

social media icons_fb_grey.png
social media icons_fb_c.png
social media icons_li_grey.png
social media icons_li_c.png
social media icons_yt_grey.png
social media icons_yt_c.png
social media icons_ig_grey.png
social media icons_ig_c.png
tada medical ab European Union

The project has received funding from the European Union's Horizon 2020 research and innovation programme under EIC Accelerator grant agreement No 961967, Fast Track to Innovation grant No 971225 and from the Eurostars-2 Joint Programme with co-funding from the European Union's Horizon 2020 research and innovation programme.


  1. Dewan, S.S. IV Therapy and Vein Access: Global Markets. BCC Res. HLC046D (2017).

  2. Chopra, V. et al. Peripherally inserted central catheter use in skilled nursing facilities: a pilot  study. J. Am. Geriatr. Soc. 63, 1894–1899 (2015)

  3. Literature study data

tada medical ab news 8.jpg

The project has received funding from EIT Health.